Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma.
Fukuokaya W, Kimura T, Yanagisawa T, Kimura S, Tsuzuki S, Koike Y, Iwamoto Y, Enei Y, Tanaka M, Urabe F, Onuma H, Honda M, Miki J, Oyama Y, Abe H, Egawa S.
Fukuokaya W, et al. Among authors: tanaka m.
Cancer Immunol Immunother. 2022 Jan;71(1):229-236. doi: 10.1007/s00262-021-02980-x. Epub 2021 Jun 8.
Cancer Immunol Immunother. 2022.
PMID: 34100985
Free PMC article.